Navigation Links
uniQure Initiates Phase I in Acute Intermittent Porphyria
Date:12/11/2012

tients will be followed for one year, and the interim results of the Phase I are expected in Q3 2013.

About acute intermittent porphyria

Acute Intermittent porphyria (AIP) is a rare genetic disease which is caused by mutations in the porphobilinogen deaminase (PBGD) gene; one of the enzymes of the heme biosynthesis pathway.  Mutations in this gene cause insufficient activity of the protein resulting in partially disruption of heme synthesis.  This in turn leads to accumulation of toxic intermediates (ALA and PBG) giving rise to a wide variety of problems including acute, severe abdominal pains, psychiatric and neurological disorders, and muscular weakness. Acute porphyric attacks can be life-threatening and the long-term consequences include irreversible nerve damage, liver cancer and kidney failure. Currently, the only curative therapy is liver transplantation and thus, new curative options are urgently needed.  Severe AIP patients are suffering poor quality of life with palliative treatments for the different symptoms including glucose or heme infusions for metabolic replacement and inhibition of toxic metabolic production.

About AIPGENE

AIPGENE is a European Commission Framework Programme 7-funded consortium (Grant Agreement number 261506) which was put together with the aim to develop the orphan gene therapy drug AAV5-AAT-PBGD (AMT-021) for the treatment of Acute Intermittent porphyria (AIP). The consortium's objective is to contribute to alleviating the negative impact of this disease on the quality of life of the patients and their families. Overall coordinator of the project is the Centre for Applied Medical Research (CIMA) at the University of Navarra, Pamplona, Spain. Apart from uniQure, other members of the consortium are the Clinical University of Navarra, Pamplona, Spain; Karolinska University Hospital, Stockholm, Sweden; German Cancer Research Center (NCT-DKFZ), Heidelberg, Germany; DIGNA Biotech, Pamplona, Spa
'/>"/>

SOURCE uniQure B.V.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. uniQure Appoints Hans Christian Rohde Chief Commercial Officer
2. uniQure Licenses RNA Interference Technology to Advance Huntingtons Disease Program
3. Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies
4. The Acute Liver Failure Study Group Initiates Phase 2a Study of OCR-002 for Treatment of Acute Liver Failure after Acetaminophen Overdose
5. Isis Pharmaceuticals Initiates Phase 1b/2a Study Of ISIS-SMNRx In Patients With Spinal Muscular Atrophy
6. Isis Initiates Phase 2 Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery
7. Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
8. Healthpoint Biotherapeutics Initiates Phase III Study of Unique Investigational Cell-Based Therapy for Venous Leg Ulcers
9. New Jersey Health Foundation Initiates Program To Spur Innovative Research
10. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
11. ImmusanT Initiates Clinical Trials of Nexvax2 Therapeutic Vaccine for Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... May 28, 2015 Research and Markets ( ... "North America Open System MRI Market - Growth, Trends ... offering. The key players in the industry ... Siemens Healthcare and Toshiba Medical Systems ... replacing CT because of its higher sensitivity and use ...
(Date:5/29/2015)... , May 28, 2015 Research ... addition of Jain PharmaBiotech,s new report "Cardiovascular ... to their offering. Drug delivery to ... other systems because of the anatomy and physiology ... nutrients to all organs of the body. Drugs ...
(Date:5/29/2015)... 29, 2015 LifeNet Health plans to enlarge ... 2015 to more than 160 people. The ... LifeNet Health,s innovative bio-implants, which are being made more ... be served. It also is a reflection of the ... "The growth and success of LifeNet Health is a ...
Breaking Medicine Technology:North America Open System MRI Market 2014-2019 with GE, Hitachi Medical, Philips Healthcare, Siemens Healthcare and Toshiba Medical Dominating 2Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 2Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 3LifeNet Health to add more than 160 jobs in 2015 2
... /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), a leading ... today that it has commenced vaccination of,volunteers for ... pandemic,influenza H5N1 vaccine. The Phase II clinical trial ... and efficacy of the pandemic,influenza H5N1 vaccine. The ...
... 11 ImClone Systems,Incorporated (Nasdaq: IMCL ... BMY ),today announced that a Phase III ... chemotherapy (vinorelbine plus cisplatin),met its primary endpoint ... in patients with advanced non-small cell lung ...
Cached Medicine Technology:Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine 2ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 2ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 3ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 4ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 5ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 6ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 7ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 8ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 9
(Date:5/30/2015)... Clarkston, Metamora, Michigan (PRWEB) May 30, 2015 ... simple procedure to lighten or stop periods, without ... hysterectomy. This procedure can reduce or stop menstrual bleeding ... of the uterus (the part that causes the bleeding), ... 10 million women suffer from heavy menstrual bleeding. ...
(Date:5/30/2015)... 30, 2015 ProIntro Magnify contains 30 self-animating ... animations. Instantly add an elegant opening title to any ... range of clean design layouts. ProIntro Magnify is created exclusively ... extremely easy to use. Simply drag a preset into the ... and parameters in the Inspector window then watch as ProIntro ...
(Date:5/30/2015)... May 30, 2015 The Brain Fitness ... coordination with ONEgeneration Senior Enrichment Center, headed by 1Heart ... de Guzman and Brain Fitness Program Director Tee Barr. ... event learned that there are many ways to enrich ... showed the residents the different ways to overcome dementia ...
(Date:5/30/2015)... May 30, 2015 The iconic American ... will be hosting a new segment on Medical Malpractice. ... of medical malpractice in the health care field. , ... thousands of medical malpractice suits were filed, roughly only ... were settled out of court, while the remaining 30% ...
(Date:5/30/2015)... May 30, 2015 The IRS released ... 2015, announcing that, “criminals used taxpayer-specific data acquired from ... approximately 100,000 tax accounts through IRS’ “Get Transcript” application. ... and street address.” , “You don’t even have ... to think it was only a matter of time, ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Provides NovaSure Treatment 2Health News:Announcing the release of ProIntro Magnify from Pixel Film Studios. 2Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 2Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 3Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 2Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 3Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 4Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 5
... DDS, and her staff will be racing to save lives ... of Baltimore,s 2009 Susan G. Komen Race for the Cure. ... Team Chincheck has raised more than $4,700 for breast cancer ... affected by breast cancer and witnessing their strength and courage ...
... some parents may be lukewarm to the H1N1 vaccination, ... of Southern California,s largest integrated, comprehensive healthcare organizations, reports ... access to the vaccine. In response, Lakeside Community Healthcare ... patients direct access to the information they need to ...
... ... tourism industry, announced the addition of certain providers of Sistemas Medicos Nacionales, S.A. de C.V. ... ... , a global health care company in the emerging medical tourism industry, announced the addition ...
... Oct. 14 Usinas,Siderurgicas de Minas Gerais S.A. - USIMINAS (OTC: USNZY) (BOVESPA: USIM3,USIM5, USIM6) ... Third Quarter 2009 Results Conference Call. Results will be, ... after Bovespa,s trading session., ... third quarter 2009 results, ...
... Peter Sheldon, Vice President of Operations for Coverall Health-Based ... will be a featured speaker at the Professional Retail ... on October 14-15 at The Fairmont Hotel in Dallas, ... Best in Your Business with Best Practices." Sheldon will ...
... Terumo ... the latest developments in its advanced DuraHeart™ Left-Ventricular Assist System at the 23rd Annual ... , ... Mich. (PRWEB) -- Terumo Heart, Inc., a wholly owned subsidiary of Terumo Corporation, today ...
Cached Medicine News:Health News:Team Chincheck Goes Miles for Smiles 2Health News:Leading Southern California Physicians Report Patient Fears About Complexities of Flu Season 2Health News:SIMNSA is added to the Satori Global Network™ in Mexico to Offer U.S. Employers Cross Border Health Benefit Options 2Health News:Webcast Alert: Usinas Siderurgicas de Minas Gerais S.A. - USIMINAS Announces Third Quarter 2009 Results Webcast 2Health News:Coverall Executive Peter Sheldon To Be Featured Speaker at PRSM Mid-Year Conference 2Health News:DuraHeart™ Third-Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio-thoracic Surgery 2Health News:DuraHeart™ Third-Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio-thoracic Surgery 3
CRP Liquid Conrtols level 2...
The AST method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma...
Enzymatic Clearance assay for the in vitro quantitative determination of LDL-cholesterol in human serum and plasma....
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Medicine Products: